syndrome (PWS) developed to address concerns regarding medical care, diagnosis, growth and development, awareness, and natural history. PWS results from errors in genomic imprinting leading to loss of paternally expressed genes due to 15q11-q13 deletion, maternal disomy 15 or imprinting defects. The 8 year study was conducted at four national sites on individuals with genetically confirmed PWS and early-onset morbid obesity (EMO) with data accumulated to gain a better understanding of the natural history, cause and treatment of PWS. Enrollment of 355 subjects with PWS and 36 subjects with EMO began in September 2006 with study completion in July 2014.
hyperphagia. Mild learning impairment and behavioral problems are also noted including self-injury, OCD, and temper tantrums (Angulo, Butler, & Cataletto, 2015; Bittel & Butler, 2005; Butler, 1990 Butler, , 2016a Butler et al., 2002; Cassidy et al., 2012) . PWS is due to errors in genomic imprinting with loss of paternally expressed genes generally from a de novo paternally derived chromosome 15q11-q13 deletion (Bittel & Butler, 2005; Butler, 1990; Butler et al., 2002; Butler, Lee, & Whitman, 2006; Cassidy, Schwartz, Miller, & Driscoll, 2012 ).
Patients with rare diseases are frequently misdiagnosed or undiagnosed. In addition, direct medical costs are higher as evident in Prader-Willi syndrome when compared with commercially insured patient counterparts without PWS at similar ages.
Recently, the total annual direct medical costs were reported to be 8.8 times greater than for patients without PWS (Shoffstall et al., 2016) . However, few drug companies conduct research into the cause or treatment of rare diseases as it is difficult for these companies to recover costs of developing treatments for such small, geographically dispersed populations. Therefore, advances in medical research and knowledge on rare diseases are fraught with delays and problems. To address these concerns, the National Each consortium in the RDCRN included active participation by patient advocacy groups. The RDCRN Coalition of Patient Advocacy Groups (CPAG) represented more than 30 of these national patient advocacy groups instrumental in outreach to the affected populations and provided a patient perspective to the development of studies helpful in support, subject recruitment and continuity of studies at each participating site. The RDCRN developed a unique web-based contact registry for patients who wish to learn about their disease and for participation in clinical studies providing a useful source of key information about rare diseases for physicians, investigators, patients, and the general public. Through the coordinated international efforts of RDCRN investigators, new approaches to the diagnosis, treatment, and prevention of rare diseases will be developed to reduce burden of these diseases. Additionally, the collaboration of physicians, investigators and patient support groups is critical for dissemination of knowledge and adopt research productivity to translate to the clinical setting. By studying the genetic component of these rare diseases, better predictions of the course of the illness and more effective, personalized treatments should be developed. The next generation of rare disease investigators trained in the RDCRN should ensure that the needs of families and patients with rare diseases will be addressed now and in the future, key to improve the quality of life of affected individuals. Our multi-site consortium was initially organized and experts in the study of PWS. The EMO subject group consisted of obese patients with childhood onset of obesity and with behavioral, cognitive, and medical issues similar to those seen in individuals with PWS and who were referred for genetics evaluation. This 5202 NIH rare disease consortium protocol was approved by the local IRB human subjects committees at each of the 4 study sites and consisted of screening, baseline, and follow-up forms for each subject. Informed consent was obtained on all subjects. The data collection process required forms to be completed prior to data entry in the computer generated database. The primary variables included the protocol for historical, physical, cognitive, behavioral, PWS genetic subtype data, cumulative time in study in years and mortality. The number of individuals with EMO was small in relationship to PWS due to enhanced recruitment effort at the four nationally recognized sites focused on PWS. However, the recruitment of those with early-onset morbid obesity/"Prader-Willi-like" without fragile X syndrome or other recognized obesity-related disorders was undertaken to collect a subset of subjects for determination of data with respect to birth history, medical problems, age of onset of obesity, mortality, cognition, psychiatric/behavioral problems, and physical/clinical features and laboratory measures. Comparisons and contrasts of data were made between the PWS and the EMO subject group as goals of our study to learn more about those with genetically confirmed PWS and those with overlapping features or clinical misdiagnoses without genetic confirmation of PWS. Array CGH, high-resolution SNP microarrays and/or MS-MLPA assays (Bittel, Kibiryeva, & Butler, 2007; Butler, Fischer, Kibiryeva, & Bittel, 2008; Papenhausen et al., 2011) were used when available to identify small deletions within the 15q11.2-q13 region, as well as in the entire genome (e.g., at least 370 obesity related genes are now recognized (Butler, McGuire, & Manzardo, 2015) which could contribute to the clinical similarity to those with PWS, an obesityrelated genetic disorder (Butler, 2016a) . The information gathered and learned during the longitudinal natural history study of 355 subjects with PWS and shared with the academic medical community should have direct impact on the care, delivery of July 2012 Sample size increased from 300 to 400. RNCA collection added. EMO criteria relaxed to recruit subjects with single gene mutation as cause for obesity.
Final patient visit January 2014
Baseline subject characteristics for both Prader-Willi syndrome (PWS) and early-onset morbid obesity (EMO) are shown separately in Table 2 . One subject with PWS was considered "enrolled" in the study but no information was provided.
services, treatment approaches and diagnosis of PWS (Angulo et al., 2015; Butler et al., 2006; Butler, Manzardo, & Forster, 2016; Cassidy et al., 2012) thereby enhancing the quality of life for affected individuals and their families.
The PWS group had appropriate molecular and cytogenetic testing to confirm a diagnosis of PWS (i.e., chromosomes, FISH analysis of chromosome 15q11-q13 probes, DNA methylation status, and where necessary, chromosome 15 DNA polymorphism studies utilizing parental DNA), and were categorized into the appropriate molecular group (i.e., deletion, uniparental disomy, and imprinting defect) (Angulo et al., 2015; Bittel & Butler, 2005; Butler, 2016a; Butler et al., 2006; Cassidy et al., 2012) . It should be noted that appropriate genetic testing of DNA methylation can correctly identify >99% of all patients with PWS (Butler et al., 2006; Driscoll et al., 1992; Kubota et al., 1996) . Patients with imprinting defects will be included, but the low frequency in this group will make statistical comparisons with its two molecular classes (i.e., small microdeletions and epimutations) challenging to detect. Participants were excluded from this part of the study if they were not genetically confirmed to have PWS using approved genetic testing methodology or were not classified as having a 15q11-q13 deletion, maternal disomy 15 or imprinting defect.
The EMO group was selected solely based on a documented medical chart history of their weight having exceeded 150% of Ideal Body Weight (IBW) or a Body Mass Index (BMI, kg/m 2 ) of greater than the 97 percentile before 4 years of age. Participants were excluded from the study if they had a known chromosomal aneuploidy, toxin exposure, CNS condition or other syndromes (e.g., fragile X syndrome). All EMO participants had a chromosomal study or a high resolution microarray analysis that would exclude chromosomal aneuploidy or deletions/duplications at the genome level prior to entry in the study. and current cognitive and behavioral data is currently ongoing and will be reported in separate publications. Table 2 shows the study subject characteristics at the time of enrollment or entry along with age category, BMI, full-scale IQ scores obtained from educational records, testing and molecular class data. Subjects in our study less than 3 years of age required annual evaluations per protocol and those greater than 3 years of age were followed biennially. The age range of participants was 10 weeks of age to 62 years at the time of enrollment. Assessments on each participant were repeated for each follow-up visit except for screening eligibility and demographics. Table 3 shows the study exposure of 598 cumulative years for the 355 individuals with PWS and 42 years for the 36 EMO subjects.
| Outcome assurances or study endpoints
Seven observed deaths were recorded while on study for the PWS and EMO subject groups. Table 4 lists additional information for the seven observed deaths during the study. The number of deaths was considered low and no formal statistical tests were done because of the incidence rate. However, this study did not yield evidence that the mortality was higher in the PWS group than in the EMO group (mortality incidence rates of 1.0 and 2.4 per 100 years exposure for
PWS and EMO, respectively).
A summary list (previously described in the section 2) of data points was created. Two assessments were considered in order to examine the completeness of the dataset generated in this rare disease consortium.
These included the patterns of early discontinuation and data collection compliance rate (percentage of forms filled out completely).
The majority of those discontinuing early did so in the first 2 years after enrollment, with death of participating subjects, voluntary withdrawal, becoming lost to follow-up secondary to moving away from the study sites or disinterest in continuing in the study relevant factors. There is a potential for bias in our dataset if subjects who discontinued early had more health issues than those completing the study. However, this concern may be attenuated to some degree by the fact that 1) a wide age range of PWS subjects enrolled and 2) the data collected at baseline was virtually complete for all subjects. Bias caused by early drop out would have been more of a concern if all subjects enrolled in the longitudinal study at baseline were of the same age. In addition, not all races were well represented in our study as 93% of participants with PWS were Caucasian. The natural history and clinical problems unique to patients with PWS in specific racial/ethnic backgrounds may not be identified or recognized in our study.
When examining the completeness of the forms collected, all study data were captured from 14 forms, 11 of which were taken at each visit.
Each form had certain required elements to be collected and if all required elements were obtained then the form was considered complete. The percent of complete forms submitted for baseline, 2 year, and 4 year time points were calculated for each of the forms. At these times, all subjects regardless of their age should have a completed visit. The percentage of complete forms ranged from 94-100% at baseline, 71-100% at 2 years, and 79-100% at 4 years. We consider the compliance rate to be adequate for a study of this size and duration.
As experts in the field, the principal investigators and their research partners are addressing several ongoing projects related to the natural history and better delineation of this rare syndrome with genotype-phenotype correlations. During this interim, we have published review articles on PWS (Butler, 2011 , 2016a ) Cassidy et al., 2012 , characterization of the nutritional phases of PWS (Miller et al., 2011) , development of syndrome-specific standardized growth charts for PWS with and without growth hormone treatment (Butler et al., 2011 , clinical reports of atypical findings in PWS (Butler, Bittel, Kibiryeva, Cooley, & Yu, 2010; Dang et al., 2016; Hassan & Butler, 2016) , study of neuropeptides (Butler, Nelson, Driscoll, & Manzardo, 2015a , 2015b and cytokines (Butler, Hossain, Sulsona, Driscoll, & Manzardo, 2015) , reproductive issues (Butler et al., 2009; Gold et al., 2014) and causes of death with survival trends utilizing an existing PWS specific mortality database Manzardo et al., 2017) . Our study of the mortality incidence rate in PWS per 100 years of exposure is novel and showed a low rate, not significantly different than that observed in the EMO group. The opportunity to address new questions and analyze this extensive clinical and genetic database is unique to this consortium and vital to gain a better understanding of the cause and diagnosis of PWS, the most common syndromic cause of morbid obesity in children (Butler, 1990) .
Funding from the NIH for the rare disease consortium for PWS and EMO ended on July 31, 2014. Funding from PWSA (USA) has been obtained in the interim and continued access to the services of the DMCC will be pursued by the members of the PWS-EMO consortium.
The principal investigators involved with the PWS and EMO consortium continue to pursue funding for long-term ongoing access to the services and statistical support of the DMCC staff. All data will be released to the NIH.
A viable long-term access to this existing, one-of-a-kind valuable dataset is important to generate reports and manuscripts to investigate and better delineate the natural history and comorbidities (recognized, unrecognized or understudied) related to PWS such as diabetes and other endocrine disturbances; growth hormone measures, treatment and outcomes; cognitive and behavioral problems in relationship to PWS genetic subtypes; mortality rates and causes of death (see Table 4 ) surgery records; family history; medications (dosage, indication, length of treatment); thrombotic and embolic events and medical problems unique to PWS in relationship to other rare genetic disorders or shared with others having similar features such as non-syndromic obesity; obesity (onset, degree, fluctuations), hyperphagia (onset, level), and nutritional status and osteoporosis. Going forward, this dataset will undoubtedly prove invaluable to academic researchers and patient advocacy groups, as well as pharmaceutical companies planning or conducting clinical trials to address problems related to PWS including hyperphagia and obesity. Special attention will be given to the more life-threatening aspects of the complex syndrome in order to find answers. However, the number of EMO participants in our study was relatively small and limits our ability to make meaningful comparisons with the PWS study group participants. A larger number of obese subjects should be recruited from different sources for genetic evaluation to compare with PWS.
Secondary study objectives included comparisons of the three PWS main molecular classes (deletion, uniparental disomy, and imprinting defect) from data collected at the various centers which was particularly crucial for identification of those with imprinting defects since these are rare. In addition, comparisons were done within the deletion class to compare those with a larger typical deletion (i.e., type I), smaller typical deletion (i.e., type II) and those with rarer atypical deletions, either smaller or larger than the typical type I or type II deletion. Study participants were recruited and enrolled from infancy through adulthood and array comparative genomic hybridization (CGH), high resolution SNP arrays, genotyping of proband, and parental DNA using chromosome 15 markers and/or MS-MLPA protocols were used when available to confirm the DNA methylation status and/or distinguish type I and type II deletions from atypical deletions or maternal disomy 15 in our PWS subjects.
Our rare disease consortium consisting of four national sites involved with standardized collection of longitudinal clinical, medical, cognitive, behavior and genetic data represents the largest PWS cohort studied to date and consisting of 355 subjects with genetic confirmation of PWS and identified genetic subtypes. We found that 61% showed a 15q11-q13 deletion, 36% had maternal disomy 15 and 3% with an imprinting defect.
The percentage of individuals with PWS in our consortium showed a lower number of deletions (61%) and a higher number for maternal disomy 15 (36%) than generally quoted in the literature, possibly due to a change in frequency related to improved genetic testing, older age of parents with delayed child bearing and better awareness and recognition of PWS.
Other clinical, psychiatric and genetic databases in PWS do exist that glean information on diagnosis, genetic subtype- and adverse events in Prader-Willi syndrome utilizing the KIGS (the Pfizer International Growth Database) (Craig et al., 2006) ; the relationship between compulsive behavior and academic achievement across the three genetic subtypes of Prader-Willi syndrome (Zarcone et al., 2007) ; the European Prader-Willi Syndrome Clinical Research Database (Holland et al., 2009);  cognitive profiling in a large French cohort of adults with PraderWilli syndrome (Copet et al., 2010) and causes of death with survival trends in Prader-Willi syndrome utilizing the PraderWilli Syndrome Association (USA) 40-year mortality survey Manzardo et al., 2017) .
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